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Abstract Influenza virus infections (IVI) may pose a vital
threat to immunocompromised patients such as those suffer-
ing from malignancies, but specific data on epidemiology and
outcome in these patients are scarce. In this study, we collect-
ed data on patients with active cancer or with a history of
cancer, presenting with documented IVI in eight centres in
Germany. Two hundred and three patients were identified,
suffering from haematological malignancies or solid tumours;
109 (54 %) patients had active malignant disease. Influenza A
was detected in 155 (77 %) and Influenza B in 46 (23 %) of
patients (genera not determined in two patients). Clinical
symptoms were consistent with upper respiratory tract infec-
tion in 55/203 (27 %), influenza-like illness in 82/203 (40 %),
and pneumonia in 67/203 (33 %). Anti-viral treatment with
oseltamivir was received by 116/195 (59 %). Superinfections
occurred in 37/203 (18%), and admission on an intensive care
unit was required in 26/203 (13 %). Seventeen patients (9 %)
died. Independent risk factors for death were delayed diagno-
sis of IVI and bacterial or fungal superinfection, but not un-
derlying malignancy or ongoing immunosuppression. In con-
clusion, patients with IVI show high rates of pneumonia and
mortality. Early and rapid diagnosis is essential. The high rate
of pneumonia and superinfections should be taken into ac-
count when managing IVI in these patients.
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Introduction
Infections are the main cause of treatment-related mortality in
cancer patients. Whereas bacterial and fungal infections are
common and well-known, infections by community acquired
respiratory viruses have often received less attention in the past.
With the emergence of nucleic acid amplification techniques
(NAT), diagnosis of specific viral infections has become easier
and faster, making it possible to gain more precise information
on epidemiology and outcome. Most studies with regard to
infections with community acquired respiratory viruses, includ-
ing influenza, in the immunocompromised host have been per-
formed in patients with haematological malignancies, especially
those following stem-cell transplantation (SCT) [1–7].
However, there is an evident need to obtain information on
the impact of IVI in patients with all kinds of malignancies, as
only a few studies have dealt with patients suffering from solid
tumours [8]. In the 2014/15 season, the wave of IVI was par-
ticularly strong in Germany [9]. It started in October 2014 from
and affecting especially the south-east of Germany spreading
from there north-west over Germany, peaked in the second
week of 2015, and lasted till mid-April 2015 [9]. A genetic drift
occurred in the dominating influenza A (H3N2) viruses (62 %),
which was not covered by the seasonal vaccine. Influenza
A(H1N1)pdm09-viruses were identified in 15 % and influenza
B viruses in 23 % of the samples tested positive for influenza
[9].
The aim of our study was to understand the clinical epide-
miology and outcome of IVI in cancer patients during the
2014/15 influenza season, in order to identify patients at risk
of a severe course of infection and mortality.
Patients and methods
All patients (out- and inpatients) with active malignancy or
history of malignant disease presenting with documented IVI
to one of the eight participating centres of the AGIHO (at the
German university hospitals of Bonn, Cologne, Halle/Saale,
Heidelberg, Jena, Magdeburg, Mainz, and Munich) between
November 2014 and June 2015 were included in this analysis.
IVI diagnosis was confirmed by tests using nucleic acid
amplification techniques (NAT) from respiratory samples.
Materials used for NAT analysis were mostly pharyngeal
swabs (almost 70 %), but pharyngeal lavage fluids or bron-
choalveolar lavage (BAL) fluids were also used. Further in-
fluenza A virus subtyping was performed if available. Most
centres also tested for respiratory syncytial virus ( RSV),
whereas the panel for other respiratory viruses including
parainfluenza and rhinoviruses varied according to the differ-
ent laboratories, and was not prespecified.
Data were collected on each site from medical records
using a predefined short questionnaire. The questionnaire
included data on demographics (age, sex), type of influenza
virus, clinical presentation of infection, treatment and out-
come, type and treatment of underlying malignant disease,
and immunosuppressive therapy, as well as presence of co-
infections. Because data on vaccination status were not avail-
able from medical records in most cases, we tried to obtain
additional information on this point by (telephone) interview
or using the influenza registry of the health authorities in Jena,
Heidelberg, and Mainz. Patients were followed with regard to
outcome until clinical resolution of the infection, discharge
from hospital, or death. Data were transferred to the coordi-
nating centre (Jena) in an anonymised form.
Influenza-like illness (ILI) is defined according to the
European Centre for Disease Prevention and Control
(ECDC) by at least one of four systemic symptoms (fever,
malaise, headache, or myalgia) and at least one respiratory
symptom (cough, sore throat, or shortness of breath). A sud-
den onset of symptoms is mandatory [10].
Upper respiratory tract infection (URTI) is anatomically
defined to include sinusitis and rhinitis and is characterized
by new onset of symptoms including at least one of cough,
coryza, sore throat, or shortness of breath.
Lower respiratory tract infection (LRTI) involving the pul-
monary parenchyma, is defined by clinical or radiological
evidence of pneumonia [11]. Severe LRTI was defined as
requirement of treatment on intensive care unit (ICU) or death.
Detection of bacterial or fungal pathogens in BAL or blood
culture (BC) was considered a relevant superinfection except
for the following conditions: In the case of coagulase-negative
staphylococci, the detection of the pathogen in at least two
different BC was required for definition as relevant superin-
fection. Enterococcus spp. were considered relevant if detect-
ed in BC but not if derived from respiratory samples.
Escherichia col i , Pseudomonas aeruginosa , and
Stenotrophomonas maltophilia cultured from pharyngeal la-
vage fluids were considered contaminants. Detection of respi-
ratory viruses in samples derived from the respiratory tract
was considered a relevant co-infection, whereas detection of
herpes viruses was classified as endogenous reactivation sec-
ondary to IVI. For statistical analysis, all types of relevant
infection were summarized and classified as superinfection.
Statistical analysis was performed with IBM SPSS statistics
software, version 21. Proportions were analysed using chi-
square tests. Time to event data were analysed using the
Kaplan–Meier method and the log-rank for univariable analy-
ses. Multivariable analyses are based on Cox regression
models. A two-sided p-value <0.05 was considered significant.
Results
A cohort of 210 cancer patients presenting with IVI was iden-
tified. Of those, complete clinical information was available in
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203 patients who were included in the final analysis. The
median follow- up interval was 127 days (range 0–236 days).
Themedian age was 61 years (interquartile range [IQR] 49–65
years) and 61 % of the patients were male (123/203, Table 1).
The majority of patients (158/203, 78 %) suffered from hae-
matological malignancies, and most (106/203, 52 %) had
received any type of SCT. There was also a considerable num-
ber of patients with solid tumours (21/203, 10 %). About half
of the patients (109/203, 54%) had activemalignant disease at
the time of IVI diagnosis (Table 1).
Initial clinical presentation included symptoms related to
URTI in 55 patients (27 %), ILI in 82 patients (40 %), and
Table 1 Patient characteristics
All Myeloid malignanciesa Lymphoid malignanciesb Solid tumours c Othersg P valued
N = 203 N = 51 N = 107 N = 21 N = 24
Age
(median, IQR)
61 (49–65) 57 (48–62) 61 (49–70) 63 (61–73) 62 (47–64) 0.019
Male:
n/N (%)
123/203 (61 %) 26/51 (51 %) 69/107 (65 %) 14/21 (67 %) 14/24 (58 %) 0.39
Active malignant disease:
n/N (%)
109/200 (55 %) 15/49 (31 %) 69/107 (65 %) 15/21 (71 %) 10/23 (44 %) <0.001
Stem cell transplantation:
n/N (%)
105/202 (52 %) <0.001
- Autologous 28/202 (14 %) 0/51 28/106 (26 %) 0/21 0/24




- A 155/201 (77 %) 41/51 (80 %) 80/107 (75 %) 15/21 (71 %) 19/24 (79 %)
- B 46/201 (23 %) 10/51 (20 %) 25/107 (23 %) 6/21 (29 %) 5/24 (21 %)




- Swab 139/203 (69 %) 33/51 (65 %) 75/107 (70 %) 9/21 (43 %) 22/24 (92 %)
- Pharyngeal lavage fluid 42/203 (21 %) 11/51 (22 %) 22/107 (21 %) 7/21 (33 %) 2/24 (8 %)
- BAL 19/203 (9 %) 6/51 (12 %) 8/107 (8 %) 5/21 (24 %) 0/24




- Asymptomatic 9/203 (4 %) 0/51 7/107 (7 %) 1/21 (5 %) 1/24 (4 %)
- URTI 55/203 (26 %) 15/51 (29 %) 19/107 (18 %) 7/21 (33 %) 14/24 (58 %)
- ILI 82/203 (39 %) 25/51 (49 %) 47/107 (44 %) 7/21 (33 %) 3/24 (13 %)
- Pneumonia 57/203f (27 %) 11/51 (22 %) 34/107 (32 %) 6/21 (29 %) 6/24 (25 %)
ICU: n/N (%) 26/201 (13 %) 6/50 (12 %) 17/107 (16 %) 3/21 (15 %) 0/24 0.2
Death from influenza: n/N (%) 17/200 (9 %) 5/50 (10 %) 10/105 (10 %) 1/21 (4 %) 1/24 (4 %) 0.7
Treatment with oseltamivir:
n/N (%)
116/195 (60 %) 31/49 (63 %) 59/102 (58 %) 14/21 (67 %) 12/23 (52 %) 0.7
Superinfectione::
n/N (%)
37/201 (18 %) 12/51 (24 %) 21/106 (20 %) 6/20 (30 %) 3/24 (13 %) 0.73
- Bacterial 14 5 7 2 0
- Fungal 10 2 6 2 0
- Viral 18 5 8 2 3
a acute myeloblastic leukaemia (AML) = 43, chronic myeloid leukaemia (CML) = 3, myelodysplastic syndrome (MDS) = 5
b acute lymphoblastic leukaemia (ALL) =13, Hodgkin’s lymphoma =11, Non Hodgkin’s lymphoma (NHL) =36, multiple myeloma (MM) = 47
c gastrointestinal tumours = 4, lung cancer = 9, gynaecological cancer = 3, primitive neuroectodermal tumour (PNET) = 1, sarcoma = 1, urothel carci-
noma = 1, melanoma = 1, larynx carcinoma = 1
d Chi-square test
e including co- infections and viral reactivation
f ten additional patients developed pneumonia later on.
g underlying malignancy not specified
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pneumonia in 57 patients (28 %). Another ten patients (5 %)
developed pneumonia later on, to account for an overall rate of
pneumonia of 33 %. Unexpectedly, 21 patients (10 %) also
complained of gastrointestinal symptoms such as diarrhoea.
Nine patients (4 %) were asymptomatic at the time of diagnosis.
In accordance with the general epidemiology, the dominat-
ing influenza virus genus was influenza A (155/201, 77 %),
including H3N2 (28 patients) and A(H1N1)pdm09 (six pa-
tients) or influenza B (46/201, 23 %; Table 1).
In total, 37 patients (18 %) were considered suffering from
relevant superinfection. Two or more different relevant path-
ogens were detected in samples from seven patients. Ten pa-
tients had bacteraemia (one with viral co-infection), and three
patients had bacterial pneumonia without positive BC.
Another ten patients had fungal pneumonia (one of them with
concomitant E. coli bacteraemia and one as a double infection
with Aspergillus fumigatus and Pneumocystis jirovecii). The
remaining 14 patients had one or more co-infecting viruses.
For a list of pathogens causing super- and co-infection, see
Table 2. The most frequent pathogens were respiratory virus-
es, enteric bacteria, and fungi. To a lesser extent, we detected
non-fermenting Gram-negative bacteria and Gram-positive
bacteria. In four cases we also found reactivation of
herpesviridae (HSV, CMV, and HHV6) during IVI,
E. faecium and S. maltophilia in respiratory samples in three
cases and in one case respectively, and contamination with
coagulase-negative staphylococci in three cases. These find-
ings were considered clinically irrelevant and thus ignored
[12].
One hundred and fourteen patients (56 %) received antivi-
ral treatment. In one case with co-infection with RSV and
parainfluenza, ribavirin was administered; all others were
treated with oseltamivir. The dose of oseltamivir was
150 mg/d in 89/114 patients (78 %), but some also received
a lower dose of 30 to 75 mg/d (14/114, 12 %). The median
duration of treatment was 7 days (IQR 6.5–7.5 days).
Information on vaccination against influenza was available
in 34 patients only. Twelve of 34 patients were vaccinated in
2014, whereas the other 22 received no vaccination.
Severe course of illness required treatment on intensive
care unit (ICU) in 26 cases (13 %). Of 67 patients with
LRTI, 23 (34 %) had to be treated on the ICU (nine with
bacterial, four with fungal, and two with viral superinfection)
and 12 of these patients (18 %) died. Overall, 17/200 patients
(9 %) died in the course of IVI (Table 3).
In univariable analysis, prognostic factors for higher mortal-
ity were bacterial and fungal superinfection (p = 0.0035,
Fig. 1a) and presence of pneumonia (p < 0.001, Fig. 1b). It
should be noted that all patients who died were suffering from
LRTI. Furthermore, time from onset of symptoms to diagnosis
of IVI was significantly different between survivors and non-
survivors (3 days [CI 95% 2–4 days] versus 7 days [CI 95% 5–
9 days], p = 0.002). Patients deceased from influenza-
associated causes were older (63 years [IQR 23–85 years]) than
patients who survived (57 years [IQR 20–85 years], p = 0.043).
In contrast, sex, type and activity of malignant disease (Fig. 1c),
immunosuppressive therapy, graft versus host disease (GvHD)
(Fig. 1d), and treatment with oseltamivir did not significantly
influence the outcome in univariable analysis. Likewise, vacci-
nation did not seem to influence mortality significantly (data
not shown). Concerning the different viral subtypes, two out of
six patients with knownA(H1N1)pdm09 infection died, in con-
trast to four out of 27 with known H3N2 infection (p = 0.08).
Multivariable analysis revealed superinfection (hazard ra-
tio [HR] 3.4 [95 % confidence interval (95%CI) 1.09–10.6,
p = 0.03) and duration from onset of symptoms to diagnosis
Table 2 Pathogens detected in respiratory samples and blood cultures




- Influenza B virus$ 1
- Metapneumovirus 1
- Adenovirus 1
- Parainfluenza virus 1
Fungi
- Aspergillus spp. 9
- Pneumocystis jirovecii 1
- Scedosporium prolificans 1
Gram-positive bacteria
- Staphylococcus aureus 1*
- Streptococcus pneumoniae 1
- Streptococcus mitis/oralis 1
- Enterococcus faecium 1
Gram-negative bacteria
- Escherichia coli 3 3
- Enterobacter cloacae 2
- Klebsiella pneumoniae 1
- Serratia marcescens 1 1
- Pseudomonas aeruginosa 3
- Stenotrophomonas maltophilia 1
BAL = bronchoalveolar lavage fluid
RSV = respiratory syncytial virus
Double and triple infections:
1× Parainfluenza virus and RSV in pharyngeal lavage fluid,
1× Pseudomonas and E. coli in BC,
1× S. mitis and E. coli in BC in addition to E. coli in BAL
1× Aspergillus and E. coli in BAL,
1× Pseudomonas in BC and adenovirus in sputum,
1× Aspergillus and pneumocystis in BAL
$ in a patient with influenza A
* in a patient with pneumonia
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(HR 1.1 [95%CI 1.01–1.2], p = 0.02) as independent prognos-
tic factors.
Discussion
Due to a high rate of LRTI and a high associated mortality
rate, the influenza season 2014/15 represented a relevant
threat to cancer patients. At presentation, a third of patients
were asymptomatic or presented with URTI only, which was
relatively unexpected from a clinician’s point of view. In line
with other reports [13], influenza-associated URTI itself was
not particularly harmful for the patients as all patients dying
from influenza suffered from or developed pneumonia in the
course of the illness. However, those patients who developed
LRTI during the course of the disease showed a relevant im-
pairment in survival (Fig. 1b), emphasising the need to take
IVI seriously regardless of initial presentation.
In our cohort, presence of superinfection and prolonged
duration from first symptoms to diagnosis were the sole
Fig. 1 a Survival of patients with or without superinfection, p = 0.0035
(log-rank). b Survival of patients with or without pneumonia, p < 0.001
(log-rank). c Survival with respect to underlying malignancy, p = 0.594
(log-rank). d Survival of patients with or without GvHD, p = 0.542 (log-
rank)
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independent prognostic factors associated with higher mortal-
ity. A variety of studies investigating the causes of death in
patients with IVI found that notably bacterial and fungal su-
perinfections played an important role with regard to morbid-
ity and mortality [14–16]. However, it seems that the mortality
in these patients varies widely between the different cohorts
[15], but the reasons for this wide scope are not clear.
Streptococcus pneumoniae, Haemophilus influenzae,
Staphylococcus aureus, E. coli, and A. fumigatus are the
superinfecting pathogens most frequently described to date
[17]. Studies on the pandemics in the twentieth century sug-
gest a high mortality due to superinfections with these patho-
gens [14]. However, in the era of widespread vaccination
against pneumococci in children and the elderly, this might
not necessarily be true anymore, as suggested by Tief et al.,
who reported a low disease severity in children co-infected
with influenza and S. pneumoniae [18]. In our cohort, 7/23
patients with bacterial or fungal infection died (30 %), show-
ing superinfection to be the strongest predictor of death.
Interestingly, we also found A. fumigatus to be a relevant
pathogen, whereas bacteria typically associated with influenza
were outnumbered by enteric bacteria and other Gram-
negative bacteria such as Pseudomonas aeruginosa. The un-
derrepresentation of Gram-positive bacteria is remarkable and
differs from previous reports [15]. The species of bacteria
found in our cohort may represent a microbial spectrum orig-
inating from the patient’s flora or from the local health care
environment. Nosocomial infections like ventilator-associated
pneumonia are known to be caused by both Gram-negative
organisms such as Pseudomonas spp., members of the
Enterobacteriacae, Acinetobacter spp., or S. maltophilia, as
well as by some Gram-positive organisms such as S. aureus
[19–22]. Unfortunately, we did not record specifically wheth-
er patients were treated as inpatients or outpatients. However,
it is not surprising to find a similar spectrum of bacteria in all
patients with malignant disease, who, if not hospitalised, usu-
ally have close contact to health care institutions. Thus, our
findings emphasise that antibiotic therapy for suspected bac-
terial superinfection in cancer patients with influenza needs to
cover Gram-positive as well as Gram-negative bacteria.
Moreover, superinfections with A. fumigatus are frequent in
patients with malignant disease and IVI, highlighting the need
for a thorough diagnostic workup and optional antifungal ther-
apy. Screening for viral co-infection was not consistent be-
tween the participating centres, which may lead to underesti-
mation of the impact of viral co- infection on the course of IVI
in patients with underlying malignant disease.
Time to diagnosis was identified as a second independent
prognostic factor for mortality in our study cohort. This may
be due to the fact that patients with pneumonia or critically ill
patients are usually considered to have other causative patho-
gens than influenza virus. Therefore, especially at the begin-
ning of a wave of influenza, these patients might be diagnosed
too late. Another possible explanation might be that patients
with prolonged diagnosis bear the risk of delaying the initia-
tion of treatment with oseltamivir, potentially leading to im-
paired efficacy of the drug [23]. In our study, time from onset
of symptoms to initiation of antiviral treatment was not re-
corded, therefore we were not able to draw any definite con-
clusion regarding this point. Nevertheless, our data support
the imperative of immediate NAT testing when cancer patients
are suspected to suffer from IVI, even at the stage of URTI, to
ensure early treatment as recommended [24, 25].
In addition to the microbial and therapy-associated risk
factors mentioned above, risk factors for severe influenza in
SCT recipients as described by the European Conference on
Infections in Leukaemia (ECIL) are: older age, lymphopenia,
first 12 months post SCT, GvHD, and immunosuppressive
therapy, as well as having an unrelated or mismatched related
donor [23]. In our study cohort, we were able to confirm that
age has an impact on mortality, whereas GvHD or immunosup-
pression and prior SCT did not influence the outcome. It is
noteworthy that severe disease did not only occur in patients
with profound immunosuppression but also in patients with no
ongoing active cancer treatment or those with solid tumours,
resulting in comparable survival rates (Fig. 1c). This is unex-
pected, since most reports of life-threatening IVI originate from
patients after allogeneic SCT, where substantial immunosup-
pression is usually an important risk factor [1, 4, 26].
Data on influenza in patients with solid tumours are gener-
ally scarce. A large study of 115 patients with solid tumours
suffering from influenza found similar results to our cohort of
21 patients with solid tumours: 23 % of these cancer patients
presented with pneumonia, and a mortality rate of 10 % was
reported [8]. In line with our results, mortality was associated
with prolonged duration to diagnosis of IVI. In contrast to our
results, ongoing immunosuppression such as cancer treatment
was associated with a severe course of viral infection, which
was not seen in our patient cohort. Additionally, in this study
detailed information on treatment with oseltamivir was pro-
vided, showing a benefit for patients being treated early [8]. In
our study, oseltamivir did not influence the outcome signifi-
cantly, possibly due to a delay of therapy.
As we conducted a retrospective study there are several
limitations of our analysis due to a lack of data with regard
to several issues. Exact information on start of antiviral
therapy is lacking as well as the inpatient/outpatient status
of the patients. Also, data on vaccination status and sub-
type of virus are very limited, and we are not able to draw
any conclusions regarding the efficacy of vaccination or
the virulence of virus subtypes. These questions will have
to be addressed in future prospective studies. Nevertheless,
all contacts of patients with malignant disease, e.g., part-
ners, household members, and health care workers, should
be urged to undergo seasonal influenza vaccination to bet-
ter protect this vulnerable collective.
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Conclusion
Albeit retrospective, some conclusions can be drawn from our
analysis:
Influenza is potentially dangerous due to high rates of
pneumonia and high mortality irrespective of the underlying
malignant disease and therefore should be taken seriously in
all groups of cancer patients. Therefore, an early diagnosis of
IVI is imperative. Superinfections need to be addressed im-
mediately and efficiently since this is the most dangerous
complication.
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